Updated Oct 15, 2026
/Haverford professor indicted for antisemitic cyberstalking campaign/Black bear enters Alaska hospital emergency room for candy/Ravens' Kyle Hamilton predicted game-winning interception after seeing Tua Tagovailoa/S&P 500 up 30.6% in Trump's second term's first 20 months/Synopsys Design IP revenue up 11% in fiscal Q3 2026/Costa Rica seeks woman suspected in American's death in Playas del Coco/Haverford professor indicted for antisemitic cyberstalking campaign/Black bear enters Alaska hospital emergency room for candy/Ravens' Kyle Hamilton predicted game-winning interception after seeing Tua Tagovailoa/S&P 500 up 30.6% in Trump's second term's first 20 months/Synopsys Design IP revenue up 11% in fiscal Q3 2026/Costa Rica seeks woman suspected in American's death in Playas del Coco
NewsSOS
← NewswireMarkets

Virax Biolabs closes $3.3 million preferred option exercise, issuing up to 548,000 ordinary shares

LONDON, July 10. A $3.3 million exercise of preferred investment options closed at Virax Biolabs Group Limited on Thursday, the company said. The close covered the purchase of up to 548,000 ordinary shares. The London-based company, which trades on Nasdaq under the ticker VRAX, had previously announced the deal.

By Simone Attah2 min read
Share

Key takeaways

  • Virax Biolabs Group Limited closed a $3.3 million exercise of preferred investment options on Thursday, July 10, 2026.
  • The exercise covered the purchase of up to 548,000 ordinary shares tied to the company's preferred investment options.
  • The $3.3 million figure represents gross proceeds, with no fees or expenses specified in the release.
  • Virax Biolabs is a London-based company listed on the Nasdaq Capital Market under the ticker symbol VRAX.
  • The company had previously announced the deal before its closing was confirmed.

LONDON, July 10. A $3.3 million exercise of preferred investment options closed at Virax Biolabs Group Limited on Thursday, the company said. The close covered the purchase of up to 548,000 ordinary shares. The London-based company, which trades on Nasdaq under the ticker VRAX, had previously announced the deal.

Transaction details

The instruments exercised were preferred investment options tied to ordinary shares of Virax Biolabs Group Limited, according to the company's release. The $3.3 million represents gross proceeds. The release did not specify fees or expenses to be deducted from that figure.

The ordinary shares carry a par value, the filing states, though the specific amount was not included in the release summary.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is listed on the Nasdaq Capital Market under the ticker symbol VRAX and is headquartered in London. The closing was confirmed in a release dated July 10, 2026.

Note: The source summary was truncated and provided limited disclosures. This article reflects only the facts contained in the available text.

Related reading

Keep reading

All bulletins →
MarketsOctober 14, 2026

BlackRock Q3 earnings beat estimates on revenue and EPS

BlackRock reported third-quarter results that exceeded analyst expectations for both adjusted earnings per share and total revenue. The asset manager posted an adjusted EPS of $15.93, surpassing the consensus estimate of $14.30 by 11.4%…

2 min read
MarketsOctober 14, 2026

StockStory Flags Hexcel as Promising Industrials Stock Amid Sector Decline

StockStory has identified Hexcel (NYSE:HXL) as an industrials stock with promising prospects, while flagging Ingersoll Rand (NYSE:IR) and D.R. Horton (NYSE:DHI) as risky positions. The analysis comes as the industrial sector has tumbled by…

2 min read
MarketsOctober 14, 2026

Fidelity data shows S&P 500 highs often precede strong returns

The S&P 500 index reached a new record high of 7,844.52 intraday on Oct. 6, a milestone that has prompted anxiety among some investors regarding potential market corrections. Fidelity researchers analyzed S&P 500 returns dating back to…

2 min read

Frequently asked

What did Virax Biolabs announce on July 10, 2026?

The company said a $3.3 million exercise of preferred investment options had closed, covering the purchase of up to 548,000 ordinary shares.

Does the $3.3 million include fees?

The $3.3 million represents gross proceeds, and the release did not specify any fees or expenses to be deducted from that figure.

Where is Virax Biolabs based and how is it traded?

Virax Biolabs Group Limited is headquartered in London and trades on the Nasdaq Capital Market under the ticker symbol VRAX.

How many ordinary shares could be issued from the exercise?

The close covered the purchase of up to 548,000 ordinary shares of Virax Biolabs Group Limited.